PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re application of:

Mickey Miller, et al.

EXAMINER: Leon B. Lankford, Jr.

Serial No.:

10/072,829

AU: 1651

Filed:

2/8/02

CONFIRMATION NO.: 2285

For:

ACROCHORDON ALLEVIATION

Mail Stop RCE Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. ED 904009146 on this the day of June, 2005 in an envelope addressed: Mail Stop RCE, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Lori Dunham

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

While this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56 it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(b) the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.



2. Identification Of Time Of Filing

This Information Disclosure Statement

			(check and complete (a), (b), (c), (d), or (e))
(a) []	accomp	anies the	new patent application submitted herewith. 37 CFR 1.97 (a)
` ' -			e months after the filing date of the application or prior to the mailing date of the first Office 37 CFR 1.97(b)
Notice o	f Allowar	nce unde	er the time period specified in §1.97(b), but before mailing of a final action under §1.113, a r §1.311, or and action that otherwise closes in the application (37 C.F.R. §1.97(c)) and is
accompa	anied by:		Statement under 37 CFR §1.97(e); or
		[]	Fee under 37 CFR §1.17(p);
(d) [] and is a	is being ccompan		the time period specified in §1.97(c), but before payment of the issue fee (37 C.F.R. §1.97(d)
		[]	Statement under 37 CFR §1.97(e); or
		[]	Fee under 37 CFR §1.17(p);
(e) [X]	is a supp	plemental	I Information Disclosure Statement under 37 CFR 1.99
<u>22, 2003</u>	• • •		ormation Disclosure Statement was filed on <u>April 30, 2002; October 2, 2002; December</u> 104; June 8, 2004; and February 28, 2005
attention		suppleme	ental Information Disclosure Statement is being submitted as the information was brought to
(f) []	The art	was enco	untered in the course of the prosecution of the corresponding foreign application(s) in

(name(s) of country(ies) and serial number(s)



FORM PTO - 1449 Modifications
List of Patents and Publications
For Applicant's Information

Disclosure Statement

(Use Several Sheets if Necessary)

ATTORNEY DOCKET NO: 6059-004

APPLICANT: M. Miller FILING DATE: 2/8/02 SERIAL NO: 10/072,829

GROUP: 1651

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

- 1. "Seborrheic and Senile Keratoses" by M.R. Caro, et al., <u>Medical Clinics of North America</u>, Vol. 35, pp. 419-431 (1951)
- 2. "Differentiating Seborrheic Keratosis from Skin Neoplasm" by R.W. Cashmore, et al., <u>Geriatrics</u>, Vol. 40, pp. 69-75 (1985)
- 3. "Curetting for Seborrheic Keratoses" by J.L. Eberlin, <u>Plastic and Reconstructive Surgery</u>, Vol. 101, No. 2, pp. 546-547 (1998)
- 4. "Malignant Melanoma Appearing in a Seborrhoeic Keratosis" by M. Jones-Caballero, et al., <u>British Journal of Dermatology</u>, Vol. 133, pp. 1016-1018 (1995)
- 5. "Cellular Response of Seborrheic Keratosis Following Croton Oil Irritation and Surgical Trauma with Special Reference to Melanoacanthoma" by B. Mevorah, et al., <u>Dermatologica</u>, Vol. 131, pp. 452-464 (1965)
- 6. "Seborrhoeic Keratoses: Scarless Removal by Curettage and Oxidized Cellulose" by F.E. Mohs, <u>Journal of the American Medical Association</u>, Vol. 212, No. 11, pp. 1956-1958 (1970)
- 7. "The Management of Seborrhoeic Keratoses by General Practitioners, Surgeons, and Dermatologists" by J.M. Sowden, et al., British Journal of Dermatology, Vol. 139, pp. 348-349 (1998)
- 8. "Cryosurgery for Common Skin Lesions: Treatment in Family Physicians' Offices" by S.J. Wetmore, <u>Canadian</u> Family Physician, Vol. 45, pp. 964-974 (1999)
- 9. "Superficial Spreading (and Disappearing) Seborrhoeic Keratosis" by R.K. Winkelmann, <u>Cutis</u>, Vol. 63, pp. 235-237 (1999)
- 10. "Malignant Melanoma Appearing in Seborrheic Keratosis" by J.B. Yakar, et al., <u>Journal of Dermatologic Surgery</u> and Oncology, Vol. 10, pp. 382-383 (1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

3. Identification Of Person(s) Making This INFORMATION DISCLOSURE STATEMENT

THE PERSON HIGHING WIL	is statement is	
(check each	applicable item (a) a	and (b))
	(a) [] the inve	entor(s) who signs below
		SIGNATURE OF INVENTOR
		Type name of inventor who is signing
	(b) [X] the atto	orney who signs below on the basis of:
		(check each applicable item)
	([] the information supplied by the inventor(s)
		[] which has been reviewed by the attorney
		[] which has not been reviewed by the attorney
J.No.: 31,872	[[X] the information in the attorney's file
,.No.: 01,07L		SIGNATURE OF ATTORNEY To May
No. (847) 770-6000		David G. Rosenbaum Type or Print Name of Attorney
		650 Dundee Road, Suite #380 P.O. Address
		Northbrook, Illinois 60062
j.No.: 42,748		SIGNATURE OF ATTORNEY for Physium's C
No. (816) 691-3248		Lana M. Knedlik Type or Print Name of Attorney
		1201 Walnut, Suite 2900 P.O. Address
		Kansas City, Missouri 64119